MBX Biosciences, Inc.
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.12M | 3.59M | 2.87M | 2.26M | 2.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.53M | 18.61M | 19.61M | 16.66M | 13.31M |
| Operating Income | -26.53M | -18.61M | -19.61M | -16.66M | -13.31M |
| Income Before Tax | -23.88M | -15.59M | -18.14M | -15.86M | -12.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.88M | -15.59M | -18.14M | -15.86M | -12.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.88M | -15.59M | -18.14M | -15.86M | -12.34M |
| EBIT | -26.53M | -18.61M | -19.61M | -16.66M | -13.31M |
| EBITDA | -26.45M | -18.55M | -19.54M | -16.60M | -13.27M |
| EPS Basic | -0.71 | -0.47 | -2.78 | -12.62 | -10.26 |
| Normalized Basic EPS | -0.45 | -0.35 | -1.74 | -7.89 | -6.41 |
| EPS Diluted | -0.71 | -0.47 | -2.78 | -12.62 | -10.26 |
| Normalized Diluted EPS | -0.45 | -0.35 | -1.74 | -7.89 | -6.41 |
| Average Basic Shares Outstanding | 33.41M | 33.39M | 6.52M | 1.26M | 1.20M |
| Average Diluted Shares Outstanding | 33.41M | 33.39M | 6.52M | 1.26M | 1.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |